The findings from a recent clinical trial indicate that a potential breakthrough drug therapy, aimed at slowing down the advancement of nearsightedness in children, may be within reach.

In a remarkable medical breakthrough, two retinologist surgeons at the Maisonneuve-Rosemont Hospital ophthalmology clinic have successfully performed groundbreaking gene therapy on an 11-year-old boy.

The US Federal Trade Commission has filed a lawsuit with the intention of preventing Amgen's $27.8 billion acquisition of Horizon Therapeutics.

A recent report from Mamavation has revealed that eighteen different types of soft contact lenses, including three major brands—Alcon, Acuvue, and Coopervision—contain detectable levels of organic fluorine.

The US Centers for Disease Control and Prevention (CDC) has provided an update on the ongoing situation involving infections caused by contaminated eye drops.

Bausch + Lomb announced that the FDA has granted approval for Miebo (perfluorohexyloctane ophthalmic solution; previously referred to as NOV03) to treat the signs and symptoms of dry eye disease (DED).

Discover how 'forever chemicals' lurking in your contact lenses could be linked to cancer risks.

Genentech announced that the FDA has accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Researchers at the Université de Montréal have made a groundbreaking discovery that offers new hope for restoring vision in patients with degenerative retinal disease.

Eyenovia Inc. announced that the FDA has approved Mydcombi, a groundbreaking ophthalmic spray that induces mydriasis for diagnostic procedures and short-term pupil dilation.